Samjin Pharm said, on April 7, it has been selected for the Ministry of Trade, Industry and Energy’s “World Class Plus Project,” a government initiative aimed at fostering globally competitive mid-sized companies.
The World Class Plus Project provides comprehensive support packages including research and development (R&D), exports, financing and consulting for selected companies in advanced industries such as biotechnology, semiconductors and artificial intelligence.
Samjin Pharm was named one of 10 mid-sized companies expected to grow into global leaders, representing the advanced biotech sector.
Through the project, the company plans to accelerate global commercialization centered on three key growth engines: expansion of indications for SJN314, development of a full-cycle antibody-drug conjugate (ADC) platform, and advancement of a next-generation controlled-release formulation platform.
SJN314, a next-generation treatment based on the MRGPRX2 mechanism, has completed preclinical studies and is entering clinical trials, with the company aiming to expand its indications and enter global markets.
The ADC platform, built on proprietary payload and linker technologies, is expected to strengthen competitiveness in cancer treatment, while the formulation platform is anticipated to enhance product competitiveness through improved drugs and establish a stable revenue base.
Lee Soo-min, head of R&D at Samjin Pharm, said the selection reflects recognition of the company’s new drug pipeline and the commercialization potential of its platform technologies, adding that it will continue expanding global technology exports based on its core pipeline and platforms.
The company currently holds 16 new drug pipeline projects and invests about 12% of its revenue in R&D. It plans to strengthen its revenue structure through expanded technology licensing and phased transfers, supported by collaboration networks with global pharmaceutical companies.
